Hepatitis C in haemophilia: lights and shadows

[Guest guest]

Haemophilia. 2004 Oct;10 Suppl 4:211-5.

Hepatitis C in haemophilia: lights and shadows.

Rumi MG, De Filippi F, Santagostino E, Colombo M.

Department of Gastroenterology and Endocrinology, A. Bianchi Bonomi

Thrombosis Center, IRCCS Maggiore Hospital, University of Milan, Italy.

Summary. Hepatitis C is a major cause of morbidity and mortality in

haemophiliacs who received clotting factor concentrates before the

availability of virus-inactivated factors in the mid-1980s. Early studies

gave conflicting indications as to the severity of hepatitis C (originally

termed non-A non-B hepatitis), as mild, slowly progressive hepatitis was

documented in several infants and young adults with haemophilia who were

examined with repeat liver biopsies, whereas more progressive hepatitis and

cirrhosis was documented in others. One major point of dispute was whether

these discrepancies could in part be accounted for by epidemiological

differences among studies, as hepatitis C acquired early in life may

initially run a benign course and later worsen owing to spontaneous

recrudescence of hepatitis or interference with such comorbidity factors as

alcohol abuse or infection with the human immunodeficiency virus (HIV). In

the mid 1990s, the latter infection overshadowed hepatitis C as a cause of

death in this patient population. Because hepatocellular carcinoma is

emerging as an important complication in haemophiliacs with long-standing

hepatitis C virus (HCV) infection who survived HIV infection, and because of

recent advances in treating HIV, morbidity and mortality associated with

chronic hepatitis C have regained emphasis amongst haemophiliacs. The

development of newer interferon-based therapies provides an opportunity for

modifying the natural history of HCV infection in a substantial number of

haemophilic patients.

PMID: 15479400 [PubMed - in process]

[Guest guest]

Haemophilia. 2004 Oct;10 Suppl 4:211-5.

Hepatitis C in haemophilia: lights and shadows.

Rumi MG, De Filippi F, Santagostino E, Colombo M.

Department of Gastroenterology and Endocrinology, A. Bianchi Bonomi

Thrombosis Center, IRCCS Maggiore Hospital, University of Milan, Italy.

Summary. Hepatitis C is a major cause of morbidity and mortality in

haemophiliacs who received clotting factor concentrates before the

availability of virus-inactivated factors in the mid-1980s. Early studies

gave conflicting indications as to the severity of hepatitis C (originally

termed non-A non-B hepatitis), as mild, slowly progressive hepatitis was

documented in several infants and young adults with haemophilia who were

examined with repeat liver biopsies, whereas more progressive hepatitis and

cirrhosis was documented in others. One major point of dispute was whether

these discrepancies could in part be accounted for by epidemiological

differences among studies, as hepatitis C acquired early in life may

initially run a benign course and later worsen owing to spontaneous

recrudescence of hepatitis or interference with such comorbidity factors as

alcohol abuse or infection with the human immunodeficiency virus (HIV). In

the mid 1990s, the latter infection overshadowed hepatitis C as a cause of

death in this patient population. Because hepatocellular carcinoma is

emerging as an important complication in haemophiliacs with long-standing

hepatitis C virus (HCV) infection who survived HIV infection, and because of

recent advances in treating HIV, morbidity and mortality associated with

chronic hepatitis C have regained emphasis amongst haemophiliacs. The

development of newer interferon-based therapies provides an opportunity for

modifying the natural history of HCV infection in a substantial number of

haemophilic patients.

PMID: 15479400 [PubMed - in process]

[Guest guest]

Haemophilia. 2004 Oct;10 Suppl 4:211-5.

Hepatitis C in haemophilia: lights and shadows.

Rumi MG, De Filippi F, Santagostino E, Colombo M.

Department of Gastroenterology and Endocrinology, A. Bianchi Bonomi

Thrombosis Center, IRCCS Maggiore Hospital, University of Milan, Italy.

Summary. Hepatitis C is a major cause of morbidity and mortality in

haemophiliacs who received clotting factor concentrates before the

availability of virus-inactivated factors in the mid-1980s. Early studies

gave conflicting indications as to the severity of hepatitis C (originally

termed non-A non-B hepatitis), as mild, slowly progressive hepatitis was

documented in several infants and young adults with haemophilia who were

examined with repeat liver biopsies, whereas more progressive hepatitis and

cirrhosis was documented in others. One major point of dispute was whether

these discrepancies could in part be accounted for by epidemiological

differences among studies, as hepatitis C acquired early in life may

initially run a benign course and later worsen owing to spontaneous

recrudescence of hepatitis or interference with such comorbidity factors as

alcohol abuse or infection with the human immunodeficiency virus (HIV). In

the mid 1990s, the latter infection overshadowed hepatitis C as a cause of

death in this patient population. Because hepatocellular carcinoma is

emerging as an important complication in haemophiliacs with long-standing

hepatitis C virus (HCV) infection who survived HIV infection, and because of

recent advances in treating HIV, morbidity and mortality associated with

chronic hepatitis C have regained emphasis amongst haemophiliacs. The

development of newer interferon-based therapies provides an opportunity for

modifying the natural history of HCV infection in a substantial number of

haemophilic patients.

PMID: 15479400 [PubMed - in process]

[Guest guest]

Haemophilia. 2004 Oct;10 Suppl 4:211-5.

Hepatitis C in haemophilia: lights and shadows.

Rumi MG, De Filippi F, Santagostino E, Colombo M.

Department of Gastroenterology and Endocrinology, A. Bianchi Bonomi

Thrombosis Center, IRCCS Maggiore Hospital, University of Milan, Italy.

Summary. Hepatitis C is a major cause of morbidity and mortality in

haemophiliacs who received clotting factor concentrates before the

availability of virus-inactivated factors in the mid-1980s. Early studies

gave conflicting indications as to the severity of hepatitis C (originally

termed non-A non-B hepatitis), as mild, slowly progressive hepatitis was

documented in several infants and young adults with haemophilia who were

examined with repeat liver biopsies, whereas more progressive hepatitis and

cirrhosis was documented in others. One major point of dispute was whether

these discrepancies could in part be accounted for by epidemiological

differences among studies, as hepatitis C acquired early in life may

initially run a benign course and later worsen owing to spontaneous

recrudescence of hepatitis or interference with such comorbidity factors as

alcohol abuse or infection with the human immunodeficiency virus (HIV). In

the mid 1990s, the latter infection overshadowed hepatitis C as a cause of

death in this patient population. Because hepatocellular carcinoma is

emerging as an important complication in haemophiliacs with long-standing

hepatitis C virus (HCV) infection who survived HIV infection, and because of

recent advances in treating HIV, morbidity and mortality associated with

chronic hepatitis C have regained emphasis amongst haemophiliacs. The

development of newer interferon-based therapies provides an opportunity for

modifying the natural history of HCV infection in a substantial number of

haemophilic patients.

PMID: 15479400 [PubMed - in process]